Biology of Inflammatory Products: Cytokines
Eosinophil Development and Bone Marrow and Tissue Eosinophils in Atopic AsthmaRobinson D.S.a · North J.a · Zeibecoglou K.a · Ying S.a · Meng Q.a · Rankin S.b · Hamid Q.c · Tavernier J.d · Kay A.B.a
aAllergy and Clinical Immunology and bLeukocyte Biology, Imperial College School of Medicine, National Heart and Lung Institute, London, UK; cMeakins Christie Laboratories, McGill University, Montreal, Canada; dDepartment of Medical Protein Chemistry, Flanders Inter–University Institute for Biotechnology, Gent, Belgium
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background: Eosinophils develop from bone marrow (BM) progenitors, and interleukin–5 (IL–5) and eotaxin may act in expansion and mobilisation of BM eosinophils in asthma. Methods: We have examined phenotypic changes as CD34+ cells develop to the eosinophil lineage in vitro, and have evaluated BM eosinophils from asthmatic and control subjects for expression of the eotaxin receptor, CCR3. Results: Acquisition of receptors for IL–5 and CCR3 was an early event in eosinophil development. There were increased CD34+ cells, and mature and immature CCR3+ eosinophils in BM from asthmatics. Conclusion: These data suggest that IL–5 may act early in eosinophil development, and that eotaxin has the capacity to mobilise a BM eosinophil pool in asthma.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.